


XTX101 – a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody – demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer



Authors

Kurt A. Jenkins, Miso Park, Magali Pederzoli-Ribeil, Ugur Eskiocak, Parker Johnson, Wilson Guzman, Megan McLaughlin, Deborah Moore-Lai, Caitlin O'Toole, Zhen Liu, Benjamin Nicholson, Veronica Flesch, Huawei Qiu, Tim Clackson, Ronan C. O'Hagan, Ulrich Rodeck, Margaret Karow, Jennifer O'Neil, John C. Williams

Correspondence

kjenkins@xiliotx.com

In Brief

Efficacy of CTLA-4 antagonists such as ipilimumab is frequently accompanied by immune-related adverse events. To this end we report the discovery efforts to generate XTX101, a tumor-activatable, Fc-enhanced anti-CTLA-4 mAb.